News | October 29, 2010

Study Site Enrollment Completed for EP Device Antibacterial Envelope

October 29, 2010 – Site enrollment has been completed for the 50-site CITADEL and CENTURION clinical studies to evaluate the Tyrx AigisRx Antibacterial Envelope. The device is designed to help reduce surgical-site infections (SSIs) associated with cardiac implantable electronic devices (CIEDs).

The trials are both large, prospective, multicenter clinical studies, which together, will enroll 4,300 subjects at 50 clinical study sites across the United States. Patients enrolled in these studies have a pacemaker, implantable cardioverter-defibrillator (ICD) or a cardiac resynchronization therapy (CRT) device that will be replaced with an ICD or CRT device accompanied by AigisRx.

In the CITADEL study, prospectively enrolled patients receiving AigisRx will be compared to published controls who have undergone pacemaker, ICD or CRT device replacement with an ICD without AigisRx.

In the CENTURION study, prospectively enrolled patients will be compared to 2000 case-matched controls that have undergone pacemaker, ICD or CRT device replacement with a CRT without AigisRx.
The primary endpoints for both studies will be 1) major ICD/CRT device-related infections and 2) ICD/CRT device-related mechanical complications. Patients will be followed for 12 months, with predefined interim analyses at three and six months.

The AigisRx Envelope is an antibacterial mesh envelope designed to deliver antimicrobial agents which help provide protection against infections associated with implanted pacemakers and ICDs/CRTs. AigisRx also securely holds a pacemaker or ICD/CRT in order to create a stable environment when implanted in the body.

“Published data shows us that the risk of CIED infection is higher for ICDs/CRTs in comparison to pacemakers. Additionally, replacement procedures carry more infection risk compared to initial implants. The CITADEL and CENTURION studies will provide vital information on the clinical performance of AIGISRx in these particularly high risk groups for CIED infection,” said Scott Burkett, M.D., FACP, FACC, Burkett Heart Clinic, Monroe, La.

Tyrx commercializes innovative, implantable combination drug/device products focused on infection control, including the AigisRx Antibacterial Envelope and AigisRx Flat Sheet products. Their products contain antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by organisms representing a majority of the infections reported in cardiac implantable electronic device (CIED)-related endocarditis, including “superbugs” or MRSA.

For more information: www.tyrx.com

Related Content

The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Merge Hemo cath lab hemodynamics monitoring system.

Hemodynamic data shown on screens from the Merge Hemo recording system. It is among the newer generation hemodynamic systems for cath labs that are more user friendly and have technologies to speed workflow.

Feature | Hemodynamic Monitoring Systems| August 03, 2017 | Dave Fornell
The current generation of...
Left Atrial Pressure Monitor from Vectorious Medical Technologies Offers New Hope for Heart Failure Patients

On of the top stories in July was the introduction of a left atrial pressure monitor from Vectorious Medical Technologies to prevent heart failure patient hospitalizations or readmissions. Read the article"Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients."

Feature | August 01, 2017 | Dave Fornell
Aug.
Ohio State Researchers Prove Human Heart's 'Battery' Has Multiple Backups
News | EP Lab| July 27, 2017
July 27, 2017 — There is good news when it comes to the heart’s sinoatrial node (SAN), the body’s natural...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT)| July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Cardiologs ECG Analysis Platform Receives FDA Clearance
Technology | ECG Monitoring Services| July 13, 2017
Cardiologs Technologies SAS announced that it has received U.S. Food and Drug Administration (FDA) clearance of its...
Overlay Init